{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-004229","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2022-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.651680+00:00","generated_at":"2026-06-26T21:29:22.576232+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Terns' TERN-201 Phase 1b AVIATION trial meets safety; no efficacy in NASH","bullets":["Part 1 of Phase 1b AVIATION trial of TERN-201 10 mg met primary safety endpoint; well-tolerated with no SAEs.","No meaningful changes in exploratory NASH biomarkers (cT1, ALT, AST, GGT, CK-18) vs placebo.","Near complete (>98%) VAP-1 inhibition achieved but no efficacy signals.","Part 2 (20 mg) ongoing; top-line results expected H2 2022.","Cash runway into 2024; pipeline includes TERN-501 Phase 2a in H1 2022 and TERN-601 Phase 1 in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-004229","json":"https://secwatch.observer/filing/0000950170-22-004229.json","markdown":"https://secwatch.observer/filing/0000950170-22-004229.md","text":"https://secwatch.observer/filing/0000950170-22-004229.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017022004229/0000950170-22-004229-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017022004229/tern-20220321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:29:22.576232+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}